Vanguard Group Inc V Tv Therapeutics Inc. Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.66 - $40.8 $430 - $26,642	653 Added 0.07%	939,623 $620,000
Q2 2022 Aug 12, 2022	SELL	$0.39 - $0.84 $319,952 - $689,127	-820,390 Reduced 46.63%	938,970 $704,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.69 $1,480 - $2,633	-1,558 Reduced 0.09%	1,759,360 $1.75 Million
Q3 2021 Nov 12, 2021	BUY	$1.53 - $2.22 $4,274 - $6,202	2,794 Added 0.16%	1,760,918 $2.7 Million
Q2 2021 Aug 13, 2021	BUY	$2.27 - $3.44 $3.99 Million - $6.05 Million	1,758,124 New	1,758,124 $4.01 Million

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.1B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.